Wavelength-Pharmaceuticals-Insert
X

Find Novel Psychiatry/Psychology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Asenapine Maleate

            Therapeutic Area: Psychiatry/Psychology Product Name: Asenapine TTS

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Livzon Pharmaceutical Group Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 06, 2020

            Details:

            LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRX-P4-003

            Therapeutic Area: Psychiatry/Psychology Product Name: PRX-P4-003

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2020

            Details:

            PRX-P4-003 is a new chemical entity (NCE) that incorporates an active isomer of fencamfamine, a well-tolerated Schedule IV stimulant. Fencamfamine has a long-established clinical profile following decades of therapeutic use in Europe and other countries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 4-Chlorokynurenine,Probenecid

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: VistaGen Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 27, 2020

            Details:

            Under this agreement, VistaGen and Nuformix initially will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naltrexone

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 22, 2020

            Details:

            In light of uncertainties across many industries due to COVID-19, BioCorRx wanted to reiterate that its pivotal GLP preclinical studies of BICX102, continue to progress and have been uninterrupted by COVID-19 to date.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabidiol,Tetramethylpyrazine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2020

            Details:

            The U.S. Patent and Trademark Office has issued a “composition of matter” patent with claims covering ART12.11, the Company’s cocrystal, solid form of CBD (cannabidiol) and TMP (tetramethypyrazine).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine,Lysergide

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2020

            Details:

            The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naltrexone

            Therapeutic Area: Psychiatry/Psychology Product Name: BICX102

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: BioCorRx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 26, 2020

            Details:

            Irisys is providing contract development and GMP manufacturing services to BioCorRx Pharmaceuticals for a sterile naltrexone sub-cutaneous implant (BICX102) used in treatment of opioid use disorder and the prevention of relapse following opioid detoxification.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naltrexone

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institute on Drug Abuse

            Deal Size: $5.7 million Upfront Cash: Undisclosed

            Deal Type: Funding January 30, 2020

            Details:

            The grant was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The grant is for the development of BICX102.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Drinabant

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Center for Advancing Translational Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 02, 2020

            Details:

            NCATS will provide development resources and funding around certain pre-clinical activities and studies in order to support Opiant’s planned filing of an IND application for OPNT004.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydrocodone Bitartrate,Acetaminophen/Paracetamol

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 02, 2020

            Details:

            In conjunction with a third party formulation developer, the formulation and manufacturing process for LTX-03 has been optimized for commercial scale.